This site is still under development. Information, features, and some organizational
aspects of the data still need further work and will change as we continue building.

Individual

Dr. Stanislaw R. Burzynski, MD, PhD

alternative cancer therapy promoter, cancer doctor, cancer researcher, controversial cancer therapy figure, doctor, founder, Interviewee, oncologist, Physician, physician-scientist, research institute founder, writer | Burzynski Clinic, Burzynski Patient Group, Burzynski Research Institute, Burzynski: Cancer Is Serious Business Documentary Series, National Cancer Institute, The Truth About Cancer | Houston | TX | USA

Details

Roles / Typesalternative cancer therapy promoter, cancer doctor, cancer researcher, controversial cancer therapy figure, doctor, founder, Interviewee, oncologist, Physician, physician-scientist, research institute founder, writer

OrganizationsBurzynski Clinic, Burzynski Patient Group, Burzynski Research Institute, Burzynski: Cancer Is Serious Business Documentary Series, National Cancer Institute, The Truth About Cancer

Websitehttps://www.cancer.gov/about-cancer/treatment/cam/hp/antineoplastons-pdq

LinkedInhttps://www.linkedin.com/company/burzynski-clinic

X / Twitterhttps://x.com/DrStanBurzynski

Facebookhttps://www.facebook.com/burzynskiclinichouston

YouTubehttps://www.youtube.com/@TheBurzynskiClinic

Summary

Physician and developer of antineoplaston therapy; featured in alternative cancer media and reviewed by NCI PDQ. Stanislaw R. Burzynski, MD, PhD, is associated with antineoplaston therapy and the Burzynski Clinic. NCI PDQ describes antineoplastons as an experimental cancer therapy developed by Burzynski and summarizes the history of NCI-reviewed clinical-trial efforts; this record should be handled as controversial/experimental cancer.

Details

Stanislaw R. Burzynski, MD, PhD, is associated with antineoplaston therapy and the Burzynski Clinic. NCI PDQ describes antineoplastons as an experimental cancer therapy developed by Burzynski and summarizes the history of NCI-reviewed clinical-trial efforts; this record should be handled as controversial/experimental cancer-therapy context, not established cancer care.